Femtosecond laser trabeculotomy for open-angle glaucoma safe in early study
Femtosecond laser image-guided high-precision trabeculotomy, or FLigHT, for primary open-angle glaucoma showed positive safety and efficacy results in a first-in-human study, according to a press release from ViaLase.
The 12-month prospective, nonrandomized study assessed the safety of FLigHT and its ability to lower IOP in a cohort of 15 eyes with open-angle glaucoma or ocular hypertension.
Image: Adobe Stock
At 12 months, no treatment-related adverse events were reported, and there was a reduction in mean IOP. No eyes needed IOP-lowering medication.
In addition, on gonioscopy, there was no evidence of scarring at the site of treatment.
“We are encouraged by the results of this study, which validate the safety of the ViaLase
technology in performing FLigHT in patients with glaucoma,” Richard Lewis, MD, chief
medical officer at ViaLase, said in the release. “We look forward to continuing this important research, with the ultimate goal of bringing a safe and effective noninvasive treatment to glaucoma patients, supported by a multicenter prospective randomized trial which is currently enrolling.”